Co-staining of the dendritic marker MAP2 with Cav-1 showed decreased MAP2 expression in the hippocampal CA1 subfield and cortex in PSAPP-SynRFP, similar to that observed in postmortem human brains of patients diagnosed with CTE, tauopathy, and AD.12 This evidence concerns the gene MAP2 and Alzheimer disease.